+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy



A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy



Zhonghua Xin Xue Guan Bing Za Zhi 34(2): 107-110



Objective Recent experimental and clinical observations have suggested that cell transplantation could be of therapeutic value for the treatment of heart failure. This study was performed to explore the efficacy and safety of intracoronary autologous mesenchymal stem cells (MSCs) transplantation for treating patients with idiopathic dilated cardiomyopathy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011703627

Download citation: RISBibTeXText

PMID: 16626573


Related references

Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. Journal of the American College of Cardiology 69(5): 526-537, 2017

Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: a pilot prospective, open-label, randomized trial. Biology of Blood and Marrow Transplantation 20(2): 236-242, 2014

Evaluation of dilated cardiomyopathy by autologous intracoronary mononuclear bone marrow cell transplantation in humans in a prospective randomized controlled clinical trial. Fudan Xuebao 34(1): 76-79, 2007

Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research 7(9): 769-780, 2014

Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular 29(3): 437-447, 2014

Experimental studies on rabbit bone marrow mesenchymal stem cells autologous transplantation into dilated cardiomyopathy. Zhonghua Xinxueguanbing Zazhi 32(12): 1095-1098, 2004

Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scandinavian Cardiovascular Journal 39(3): 150-158, 2005

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. Plos one 9(12): E113936, 2014

Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. Journal of Cardiovascular Medicine 18(4): 283-290, 2017

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Multiple Sclerosis 18(6): 825-834, 2012

A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. New England Journal of Medicine 321(16): 1061-1068, 1989

Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307(11): 1169-1177, 2012

Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatric Transplantation 15(8): E183, 2011

Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. Journal of Gastroenterology and Hepatology 29(8): 1620-1628, 2014

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308(22): 2369-2379, 2012